Pamela Conley
Founder chez Nuvig Therapeutics, Inc.
Profil
Pamela B.
Conley is the founder of Nuvig Therapeutics, Inc. She is currently the Director at Cellphire, Inc. since 2022.
Previously, she held positions as Director at COR Therapeutics, Inc., Senior Director-Biology at Millennium Pharmaceuticals, Inc., Vice President-Research Biology at Portola Pharmaceuticals, Inc., and Vice President-Research at iPierian, Inc. Dr. Conley completed her undergraduate degree at The University of Texas at Austin and obtained a doctorate degree from the University of California, Berkeley.
Postes actifs de Pamela Conley
| Sociétés | Poste | Début |
|---|---|---|
Cellphire, Inc.
 Cellphire, Inc. BiotechnologyHealth Technology Cellphire, Inc. develops proprietary method for the long-term stabilization of platelets in the dry state. It focuses on developing stabilized cellular materials for advanced technologies in the therapeutic and diagnostic markets through its proprietary cell stabilization technology. The company was founded by Richard O. Cliff in 2005 and is headquartered in Rockville, MD. | Director/Board Member | 08/02/2022 |
Nuvig Therapeutics, Inc.
 Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Founder | - |
Anciens postes connus de Pamela Conley
| Sociétés | Poste | Fin |
|---|---|---|
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Director/Board Member | - |
iPierian, Inc.
 iPierian, Inc. Pharmaceuticals: MajorHealth Technology ierian, Inc. developed and manufactured biopharmaceutical products. The firm's lead antibody, IPN007, represents a new approach to treating neurodegenerative disease by targeting a novel form of secreted Tau protein. The company was founded in 2007 and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | - |
| PORTOLA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Pamela Conley
| The University of Texas at Austin | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
iPierian, Inc.
iPierian, Inc. Pharmaceuticals: MajorHealth Technology ierian, Inc. developed and manufactured biopharmaceutical products. The firm's lead antibody, IPN007, represents a new approach to treating neurodegenerative disease by targeting a novel form of secreted Tau protein. The company was founded in 2007 and is headquartered in South San Francisco, CA. | Health Technology |
Cellphire, Inc.
Cellphire, Inc. BiotechnologyHealth Technology Cellphire, Inc. develops proprietary method for the long-term stabilization of platelets in the dry state. It focuses on developing stabilized cellular materials for advanced technologies in the therapeutic and diagnostic markets through its proprietary cell stabilization technology. The company was founded by Richard O. Cliff in 2005 and is headquartered in Rockville, MD. | Health Technology |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Health Technology |
